title: Abbott outbids Biogen for Facet's multiple sclerosis antibody.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000191:economics / Q000458:organization & administration; D002986:Clinical Trials as Topic; D003164:Competitive Bidding; D000077561:Daclizumab; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration; D006801:Humans; D007074:Immunoglobulin G; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D000077561:Daclizumab
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
references.pmid: 16585503
references.citation: J Clin Immunol. 2007 Jan;27(1):1-18
references.pmid: 17216565
references.citation: Lancet Neurol. 2010 Apr;9(4):381-90
references.pmid: 20163990